Alcista
$75.33
Precio del escenario
$54.530
-0.523 (-0.96%)Al cierre
Moelis & Company is a global independent investment bank that provides strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors. The Company assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across various industry sectors. It advises clients on their critical decisions, including mergers and acquisitions (M&A), recapitalizations and restructurings, capital markets transactions, private fund raisings and secondary transactions and other corporate finance matters. It has an M&A and strategic advisory franchise advising clients on mergers, acquisitions and divestitures, spin-offs, joint ventures, fairness opinions and shareholder advisory across all sectors. For its clients seeking capital market solutions, it also structures and executes customized financing solutions and advises clients on all aspects of public and private equity and debt transactions.
Moelis & Co is currently trading at $54.53, which is below several analyst price targets, including $68 from BofA and $77 from Morgan Stanley. However, the stock has shown a year-to-date decline of 23.43%, indicating significant underperformance. The RSI is at 46.39, suggesting it is nearing oversold territory, but the MACD is negative, indicating bearish momentum. The main risk is the declining earnings per share, which has fallen by 9.1% annually, reflecting challenges in profitability. Given these factors, it may be prudent to hold rather than buy at this time, waiting for clearer signs of recovery or improvement in earnings.
BofA
$68
2026-10-12
BofA
2026-10-12
Precio objetivo
$68
Morgan Stanley
$77
2026-10-08
Morgan Stanley
2026-10-08
Precio objetivo
$77
UBS
$59
2026-10-07
UBS
2026-10-07
Precio objetivo
$59
Keefe Bruyette
$66
2026-10-07
Keefe Bruyette
2026-10-07
Precio objetivo
$66
BMO Capital
$60
2026-10-06
BMO Capital
2026-10-06
Precio objetivo
$60
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Latest Wall Street Rating Updates

European Stock Markets Close Higher on Friday

One Profitable Stock to Watch and Two Facing Challenges

Moelis & Company Reports Record Q2 2026 Earnings Driven by Capital Markets Growth

Weakness Emerging in Luxury Consumer Market
Moelis & Company is a global independent investment bank that provides strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors. The Company assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across various industry sectors. It advises clients on their critical decisions, including mergers and acquisitions (M&A), recapitalizations and restructurings, capital markets transactions, private fund raisings and secondary transactions and other corporate finance matters. It has an M&A and strategic advisory franchise advising clients on mergers, acquisitions and divestitures, spin-offs, joint ventures, fairness opinions and shareholder advisory across all sectors. For its clients seeking capital market solutions, it also structures and executes customized financing solutions and advises clients on all aspects of public and private equity and debt transactions. It operates in the Financials sector (INVESTMENT ADVICE industry).
Moelis & Co is currently trading at $54.53, which is below several analyst price targets, including $68 from BofA and $77 from Morgan Stanley. However, the stock has shown a year-to-date decline of 23.43%, indicating significant underperformance. The RSI is at 46.39, suggesting it is nearing oversold territory, but the MACD is negative, indicating bearish momentum. The main risk is the declining earnings per share, which has fallen by 9.1% annually, reflecting challenges in profitability. Given these factors, it may be prudent to hold rather than buy at this time, waiting for clearer signs of recovery or improvement in earnings.
9 analysts cover MC: 5 rate it Buy, 4 Hold and 0 Sell. The average price target is 76.57.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.